American Association for Cancer Research
00085472can121882-sup-can-12-1882methfig1-6.pdf (270.87 kB)

Supplementary Methods, Figures 1 - 6 from Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells

Download (270.87 kB)
journal contribution
posted on 2023-03-30, 22:04 authored by Gil Redelman-Sidi, Gopa Iyer, David B. Solit, Michael S. Glickman

PDF file - 270K, Figure S1: Gating strategy for flow cytometry Figure S2: Effect of small-molecule inhibitors on the uptake of fixed BCG Figure S3: Uptake of organisms other than BCG Figure S4: BCG uptake is independent of dynamin and clathrin Figure S5: Effect of dynamin constructs and clathrin shRNA on uptake of fluorescent transferrin Figure S6: Effect of BKM120 on BCG uptake



Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that is used widely as a vaccine for tuberculosis and is used as an effective treatment for superficial bladder carcinoma. Despite being the most successful cancer biotherapy, its mechanism of action and response determinants remain obscure. Here, we establish a model system to analyze BCG interaction with bladder cancer cells, using it to show that these cells vary dramatically in their susceptibility to BCG infection. Unexpectedly, the uptake of BCG by bladder cancer cells occurs by macropinocytosis rather than phagocytosis. BCG entry into bladder cancer cells relied upon Rac1, Cdc42, and their effector kinase Pak1. The difference in susceptibility between BCG-permissive and -resistant bladder cancer cells was due to oncogenic activation of signaling pathways that activate macropinocytosis, with phosphoinositide 3-kinase inhibitor activation stimulating BCG uptake independently of Akt. Similarly, activated Ras strongly activated Pak1-dependent uptake of BCG. These results reveal that oncogenic activation of macropinocytosis determines BCG uptake by bladder cancer cells, implying that tumor responsiveness to BCG may be governed by the specific mutations present in the treated cancer cell. Cancer Res; 73(3); 1156–67. ©2013 AACR.

Usage metrics

    Cancer Research



    Ref. manager